Rx Client Successes
- For more than 25 years, have worked with S&P 500® company, Alexandria Real Estate Equities, a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. Over this time, Alexandria’s equity market cap has increased from $364 million up to $23 billion.
- Worked with Alexion Pharmaceuticals for 19 years, successfully expanding the company’s institutional shareholder base from 30% to 95%.
- Have worked with Immunic Therapeutics since its reverse merger and Nasdaq listing, implementing a proactive IR program including messaging, introductions to institutional investors and sell-side analysts as well as media relations. In less than 18 months, Immunic completed an additional $170 million in capital raises, added six covering analysts and grew its market cap from $120 million to $410 million.
- Engaged by MetaVia Inc. (formerly NeuroBo Pharmaceuticals, Inc.) to lead investor positioning and execute a targeted non-deal roadshow program focused on introducing management to fundamental healthcare investors and expanding the institutional shareholder base. The initiative culminated in a $70 million capital raise and an additional $19.3 million in subsequent financings.
- Advised Intensity Therapeutics, Inc., in advance of its IPO, supporting investor positioning and facilitating introductions to institutional healthcare investors to build awareness and long-term sponsorship. The company successfully completed its public offering, generating approximately $18.9 million in net proceeds.
- Hired by Genmab A/S to work with management, company attorneys and banking syndicate, to provide strategic counsel in preparation for its U.S. IPO. Result was the second largest IPO in the history of biotech at the time, raising approximately $580 million.
- Hired by preclinical company, Morphic Therapeutic, to provide strategic counsel to management, attorneys and banking syndicate in preparation for its U.S. IPO. Company raised $103.5 million.
- Served as an integral part of Autolus Therapeutics’ IPO transaction team, which netted $160.4 million before expenses. Currently assisting with U.S. IR responsibility.
- Implemented vigorous, four-cities-a-month non-deal roadshow for Dicerna Pharmaceuticals after stock dropped following the announcement of a convertible preferred stock financing. Stock price increased 65% while trading volume doubled within five months.
- Tapped by the Alexandria Real Estate Equities team to become a preferred partner for its Alexandria LaunchLabs® member companies, providing early-stage life sciences and healthcare companies with strategic communications support and investor relations advisory services.
- For three consecutive years engaged by DNB Carnegie, the leading investment bank and wealth manager in the Nordics, to provide investor relations support for its annual Nordic-American Healthcare Conference in New York City. Managed all aspects of U.S. healthcare investor participation, including coordinating attendance and arranging high-quality one-on-one meetings between presenting companies and top-tier investors.